Prof Andrea Sartore-Bianchi (NTRK CONNECT) has developed this resource with COR2ED.
Prof Andrea Sartore-Bianchi (NTRK CONNECT) has developed this resource with COR2ED.
Andrea Sartore-Bianchi is the Director of the Division of Clinical Research and Innovation at Grande Ospedale Metropolitano Niguarda in Milano, Italy, and Associate Professor of Oncology at the University of Milano. He received his MD and postgraduate degree in Oncology at the University of Pavia, Italy, and subsequently conducted preclinical research at Brown University, Providence, RI, USA.
His main clinical and research interests include precision oncology and the treatment of gastrointestinal cancers, particularly colorectal carcinomas, focusing on biomarkers of sensitivity/resistance to targeted therapies. He is principal and co-investigator in Phase I-III clinical trials for solid tumours and carried out initial studies paving the way for the use of RAS and Her2 as tumor tissue/ctDNA biomarkers in colorectal cancer. He has published 200 peer-reviewed articles in various medical journals with a H-index of 62 (Scopus).
Amgen, Bayer, Sanofi and Servier Pharmaceuticals.
Expert insights on the latest data in oncogene-addicted non-small cell lung cancer
Two perspectives, one aim: A pathologist and a medical oncologist in discussion
Unmet needs, therapy management, and real-world experience